- Details
- Martin Gleave presents on the topic of testosterone measurement and its various nuances in the context of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Testosterone measurement is important as androgens are the drivers of activity of the androgen receptor. Dr. Gleave supports the periodic assessment of testosterone levels to ensure castrate levels, wit...
|
- Details
- Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies...
|
- Details
- In this presentation, Mark Frydenberg presents the topic of hot flushes caused by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Hot flushes are defined as a subjective feeling of warmth in the upper torso, followed by excessive perspiration. Dr. Frydenberg focuses on the various treatment options for hot flushes, including medical treatments...
|
- Details
- Inge van Oort presented the topic of managing sexuality and incontinence issues in patients with advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). When assessing sexual symptoms she references the EAU guidelines on sexual activity and the percentage of prostate cancer patients that will receive androgen deprivation therapy (ADT) at some point in the diseas...
|
- Details
- In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...
|
- Details
- At the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Alberto Briganti shares his thoughts on where he would like to see the treatment of locally advanced prostate cancer in the future. Dr. Briganti's presentation covers 4 major areas where he views opportunity for progress: the intensification of tailored multi-modal approaches, image-guided surgery, the use of novel tools to improve...
|
- Details
- Matthew Smith presented a summary detailing the best use of osteoclast-targeted therapy for patients with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Emphasizing the importance to distinguish between skeletal-related events and fragility fractures secondary to osteoporosis, Dr. Smith covers the current landscape fo...
|
- Details
- Charles Ryan presented the management of fatigue and cognitive changes induced by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Ryan discusses the association between ADT and dementia, and also how combining ADT with abiraterone and prednisone can significantly improve fatigue in patients. Biographies: Charles J. Ryan, MD , the President...
|
- Details
- Neal Shore presents on the metabolic complications of androgen deprivation therapy and how to manage them at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Biography: Neal Shore, MD , Medical Director for the Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA. Related Content: APCCC 2019: Management of Metabolic Changes Download Presentation Slides Read the Full...
|
- Details
- Karim Fizazi presented on global access to treatment of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). He includes data on current access to radiotherapy on a worldwide level, the use of generic drugs, including docetaxel, abiraterone, and cabazitaxel expected to start in 2021. Lastly, he highlights the use of surgical castration vs. the use of LHRH ago...
|
